Which of the following is NOT a part of the workup for dyslipidemia?

Monitoring renal function is not a standard part of the workup for dyslipidemia. The primary objective when evaluating dyslipidemia involves focusing on lipid levels, specifically assessing the patient's lipid panel, which includes measurements of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides.

Obtaining a fasting lipid panel is crucial because it provides accurate triglyceride and cholesterol levels, which are essential for making treatment decisions. Determining triglyceride goals is also a vital step, as it helps establish specific target levels for managing dyslipidemia based on guidelines that address both increased cardiovascular risk and individual patient factors.

Calculating risk assessment is equally important, as it evaluates the patient's overall cardiovascular risk profile, which is often guided by factors such as age, sex, family history, and other comorbidities. This risk assessment informs treatment guidelines and aids in determining the necessity and intensity of intervention.

While renal function may be monitored as part of overall health management, especially in patients with other comorbid conditions or those on certain lipid-lowering treatments (like statins), it is not a primary component of the workup specifically aimed at diagnosing or managing dyslipidemia.